ロード中...
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
BACKGROUND: Mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor vemurafenib have significantly improved the prognosis of BRAF-mutated metastatic melanoma. Some ocular symptoms and signs were recently recognized to fo...
保存先:
| 出版年: | Radiol Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Sciendo
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6043881/ https://ncbi.nlm.nih.gov/pubmed/30018526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2018-0002 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|